Trials / Conditions / Fumarate Hydratase Deficient Renal Cell Carcinoma
Fumarate Hydratase Deficient Renal Cell Carcinoma
3 registered clinical trials studyying Fumarate Hydratase Deficient Renal Cell Carcinoma.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Unknown | A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC NCT05877820 | RenJi Hospital | Phase 2 |
| Completed | Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma NCT04068831 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Active Not Recruiting | A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma NCT03635892 | Memorial Sloan Kettering Cancer Center | Phase 2 |